» Articles » PMID: 23863622

Cross-species Malaria Immunity Induced by Chemically Attenuated Parasites

Abstract

Vaccine development for the blood stages of malaria has focused on the induction of antibodies to parasite surface antigens, most of which are highly polymorphic. An alternate strategy has evolved from observations that low-density infections can induce antibody-independent immunity to different strains. To test this strategy, we treated parasitized red blood cells from the rodent parasite Plasmodium chabaudi with seco-cyclopropyl pyrrolo indole analogs. These drugs irreversibly alkylate parasite DNA, blocking their ability to replicate. After administration in mice, DNA from the vaccine could be detected in the blood for over 110 days and a single vaccination induced profound immunity to different malaria parasite species. Immunity was mediated by CD4+ T cells and was dependent on the red blood cell membrane remaining intact. The human parasite, Plasmodium falciparum, could also be attenuated by treatment with seco-cyclopropyl pyrrolo indole analogs. These data demonstrate that vaccination with chemically attenuated parasites induces protective immunity and provide a compelling rationale for testing a blood-stage parasite-based vaccine targeting human Plasmodium species.

Citing Articles

ATG5-regulated CCL2/MCP-1 production in myeloid cells selectively modulates anti-malarial CD4 Th1 responses.

Gao Y, Chen S, Jiao S, Fan Y, Li X, Tan N Autophagy. 2024; 20(6):1398-1417.

PMID: 38368631 PMC: 11210915. DOI: 10.1080/15548627.2024.2319512.


Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites.

Lopez-Perez M, Jain A, Davies D, Vasquez-Jimenez J, Herrera S, Onate J Sci Rep. 2024; 14(1):2790.

PMID: 38307966 PMC: 10837454. DOI: 10.1038/s41598-024-53175-0.


Malaria Vaccines: Progress to Date.

Stanisic D, Good M BioDrugs. 2023; 37(6):737-756.

PMID: 37728713 PMC: 10581939. DOI: 10.1007/s40259-023-00623-4.


Malaria vaccines: the 60-year journey of hope and final success-lessons learned and future prospects.

El-Moamly A, El-Sweify M Trop Med Health. 2023; 51(1):29.

PMID: 37198702 PMC: 10189698. DOI: 10.1186/s41182-023-00516-w.


Live Vaccination with Blood-Stage 17XNL Prevents the Development of Experimental Cerebral Malaria.

Imai T, Ngo-Thanh H, Suzue K, Shimo A, Nakamura A, Horiuchi Y Vaccines (Basel). 2022; 10(5).

PMID: 35632518 PMC: 9145751. DOI: 10.3390/vaccines10050762.


References
1.
Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A . Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg. 1997; 57(4):495-500. DOI: 10.4269/ajtmh.1997.57.495. View

2.
Good M, Xu H, Wykes M, Engwerda C . Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu Rev Immunol. 2005; 23:69-99. DOI: 10.1146/annurev.immunol.23.021704.115638. View

3.
Sagara I, Dicko A, Ellis R, Fay M, Diawara S, Assadou M . A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009; 27(23):3090-8. PMC: 2713037. DOI: 10.1016/j.vaccine.2009.03.014. View

4.
Epstein J, Tewari K, Lyke K, Sim B, Billingsley P, Laurens M . Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science. 2011; 334(6055):475-80. DOI: 10.1126/science.1211548. View

5.
Playfair J, de Souza J, Dockrell H, Agomo P, Taverne J . Cell-mediated immunity in the liver of mice vaccinated against malaria. Nature. 1979; 282(5740):731-4. DOI: 10.1038/282731a0. View